JP2006508637A - 胎盤成長因子1型の変異タンパク質、その調製方法及び応用 - Google Patents
胎盤成長因子1型の変異タンパク質、その調製方法及び応用 Download PDFInfo
- Publication number
- JP2006508637A JP2006508637A JP2004506360A JP2004506360A JP2006508637A JP 2006508637 A JP2006508637 A JP 2006508637A JP 2004506360 A JP2004506360 A JP 2004506360A JP 2004506360 A JP2004506360 A JP 2004506360A JP 2006508637 A JP2006508637 A JP 2006508637A
- Authority
- JP
- Japan
- Prior art keywords
- mutant protein
- protein
- plgf
- treatment
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008300 Mutant Proteins Human genes 0.000 title claims abstract description 91
- 108010021466 Mutant Proteins Proteins 0.000 title claims abstract description 91
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 title claims abstract description 72
- 102100035194 Placenta growth factor Human genes 0.000 title claims abstract description 72
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 64
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 60
- 235000018102 proteins Nutrition 0.000 claims abstract description 54
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims abstract description 11
- 239000002537 cosmetic Substances 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 64
- 230000014509 gene expression Effects 0.000 claims description 41
- 210000004027 cell Anatomy 0.000 claims description 37
- 239000000539 dimer Substances 0.000 claims description 23
- 108020004705 Codon Proteins 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 17
- 238000003752 polymerase chain reaction Methods 0.000 claims description 17
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 230000002491 angiogenic effect Effects 0.000 claims description 15
- 238000006467 substitution reaction Methods 0.000 claims description 14
- 108091034117 Oligonucleotide Proteins 0.000 claims description 13
- 235000001014 amino acid Nutrition 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 210000003000 inclusion body Anatomy 0.000 claims description 13
- 230000035772 mutation Effects 0.000 claims description 13
- 238000000746 purification Methods 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 12
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 12
- 235000018417 cysteine Nutrition 0.000 claims description 12
- 230000006698 induction Effects 0.000 claims description 12
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 12
- 239000000178 monomer Substances 0.000 claims description 12
- 230000003287 optical effect Effects 0.000 claims description 12
- 230000009089 cytolysis Effects 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 108020004414 DNA Proteins 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 230000000699 topical effect Effects 0.000 claims description 10
- 241000588724 Escherichia coli Species 0.000 claims description 9
- 239000000654 additive Substances 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 206010039710 Scleroderma Diseases 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000008030 elimination Effects 0.000 claims description 8
- 238000003379 elimination reaction Methods 0.000 claims description 8
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 230000000302 ischemic effect Effects 0.000 claims description 7
- 230000002441 reversible effect Effects 0.000 claims description 7
- 201000004384 Alopecia Diseases 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 6
- 208000028867 ischemia Diseases 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 230000001575 pathological effect Effects 0.000 claims description 6
- 230000008929 regeneration Effects 0.000 claims description 6
- 238000011069 regeneration method Methods 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 239000004202 carbamide Substances 0.000 claims description 5
- 230000003676 hair loss Effects 0.000 claims description 5
- 208000024963 hair loss Diseases 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 230000002107 myocardial effect Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000002243 precursor Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000013578 denaturing buffer Substances 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 239000000411 inducer Substances 0.000 claims description 4
- 238000004255 ion exchange chromatography Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 3
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 238000007792 addition Methods 0.000 claims description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 229940041514 candida albicans extract Drugs 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 3
- 229960004198 guanidine Drugs 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 108091008146 restriction endonucleases Proteins 0.000 claims description 3
- 229940104230 thymidine Drugs 0.000 claims description 3
- 239000012138 yeast extract Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 206010022680 Intestinal ischaemia Diseases 0.000 claims description 2
- 208000021908 Myocardial disease Diseases 0.000 claims description 2
- 206010034576 Peripheral ischaemia Diseases 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 238000005349 anion exchange Methods 0.000 claims description 2
- 230000006037 cell lysis Effects 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 claims description 2
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 claims description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 230000002980 postoperative effect Effects 0.000 claims description 2
- 238000001742 protein purification Methods 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 206010063493 Premature ageing Diseases 0.000 claims 1
- 208000032038 Premature aging Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 150000003863 ammonium salts Chemical class 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 208000023589 ischemic disease Diseases 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000002265 redox agent Substances 0.000 claims 1
- 231100000019 skin ulcer Toxicity 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 210000003491 skin Anatomy 0.000 description 21
- 239000000499 gel Substances 0.000 description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 229960002433 cysteine Drugs 0.000 description 11
- 238000001962 electrophoresis Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000033115 angiogenesis Effects 0.000 description 10
- 238000000855 fermentation Methods 0.000 description 10
- 230000004151 fermentation Effects 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 239000013543 active substance Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 108010076504 Protein Sorting Signals Proteins 0.000 description 8
- 229920002125 Sokalan® Polymers 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000001243 protein synthesis Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108010006654 Bleomycin Proteins 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 229960001561 bleomycin Drugs 0.000 description 5
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000004209 hair Anatomy 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000000527 sonication Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 210000001236 prokaryotic cell Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000011735 C3H mouse Methods 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000005571 anion exchange chromatography Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 229960001317 isoprenaline Drugs 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000003658 preventing hair loss Effects 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000007762 w/o emulsion Substances 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 241000701867 Enterobacteria phage T7 Species 0.000 description 2
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 2
- 206010040867 Skin hypertrophy Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108010006886 Vitrogen Proteins 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229960003151 mercaptamine Drugs 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 238000013425 morphometry Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000011824 nuclear material Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 238000012808 pre-inoculation Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 230000009772 tissue formation Effects 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- KYNFOMQIXZUKRK-UHFFFAOYSA-N 2,2'-dithiodiethanol Chemical compound OCCSSCCO KYNFOMQIXZUKRK-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 108010082093 Placenta Growth Factor Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 229940031955 anhydrous lanolin Drugs 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012504 chromatography matrix Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 208000004267 erosive arthropathy Diseases 0.000 description 1
- AZHSSKPUVBVXLK-UHFFFAOYSA-N ethane-1,1-diol Chemical compound CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000003660 hair regeneration Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007654 ischemic lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940042129 topical gel Drugs 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000008307 w/o/w-emulsion Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
配列番号1 シグナルペプチドのない野生型PLGF−1のヌクレオチド配列。
配列番号2 天然のPLGF−1のヌクレオチド配列。
配列番号3 PCRにおいて順方向プライマーとして使用されるオリゴヌクレオチド配列。
配列番号4 PCRにおいて逆方向プライマーとして使用されるオリゴヌクレオチド配列。
タンパク質合成がaraBADプロモーターの制御下に置かれ、様々な菌株の大腸菌(E.coli)中でアラビノースを用いて誘導することができるpBAD発現系(In vitrogen BV);
タンパク質合成がファージT7に対するRNAポリメラーゼプロモーターによって制御され、ラクトース、イソプロピル−β−D−チオガラクトピラノシド(IPTG)、又はその誘導体、又は機能的に等価なその類似体(analogous)を用いて誘導することができるT7発現系(In vitrogen BV又はPromega)。この場合、大腸菌(E.coli)のタイプDE3(Bl21(DE3)又はJM109(DE3))誘導体、すなわち、ラクトース誘導プロモーターの制御下に置かれたファージT7 Rnaポリメラーゼ遺伝子のコピーを含む誘導体を使用する必要がある;
タンパク質合成がハイブリッドプロモーターtrcの制御下に置かれたTrc発現系(In vitrogen BV)。このプロモーターは、trpプロモーターをlacプロモーターと融合させて得られ、様々な菌株の大腸菌(E.coli)中でラクトース又はそれに類似した等価物(IPTG)によって誘導することができる;
タンパク質合成がtacプロモーターの制御下に置かれたTac発現系(Amersham biosciences)。この系においては、タンパク質合成は、大腸菌(E.coli)lacIq(タイプJM105)菌株中でラクトース又はそれに類似した等価物(IPTG)によって誘導される。
タンパク質合成がPLプロモーターの制御下に置かれ、トリプトファンを添加して誘導することができるP L 発現系。この場合、トリプトファン誘導プロモーターの制御下で、ラムダファージのcIリプレッサーをコードする遺伝子のコピーを含む大腸菌(E.coli)誘導体(GI724)を使用する必要がある。
本発明者らはPlGF−1CGと呼ぶPlGF−1変異タンパク質を、チミジン(T)N°382(配列番号1)のグアニジン(G)への変異によって産生させた。このようにして、システインをコードする上記配列のTGCコドン、ヌクレオチド382〜384を、グリシンをコードするGGCに変換した。
のオリゴ1(順方向プライマー)。これは、NdeI部位(下線部)及び開始コドン(太字)を含む。
のオリゴ2(逆方向プライマー)。これは、システインをコードするTGCコドンを、グリシンをコードするGGCコドン(太字)に変換した変異T→G(下線部と太字のヌクレオチド)を含む。
微生物[Bl21(DE3)pLysS PLGF−1CG]を、培地として以下を含む溶液SBMを使用して発酵槽中で培養した。
溶液A(1リットル当たり)
バクト(Bacto)酵母抽出物(Difco) 34g
硫酸アンモニウム 2.5g
グリセリン 100ml
H2O 適量(計900ml)
溶液B(10X)(100ml当たり)
KH2PO4 1.7g
K2HPO4−3H2O 20g
又は
K2HPO4 15.26g
H2O 適量(計100ml)
PlGF−1CG変異タンパク質を食塩水溶液に理論濃度20、5及び1mg/mlで溶解させた。同時に(変異のない)PLGF−1タンパク質も食塩水溶液に濃度20mg/mlで溶解させた。すべての試料を冷蔵庫(4〜8℃)に最高40日間保存した。
PlGF−1CG変異タンパク質及び非変異PLGF−1タンパク質を濃度0.2mg/mlで以下の組成のゲル中に溶解した。
CARBOPOL 940= 1%P/V
酢酸ナトリウム pH4.4= 15mM
EDTA pH未調製(non pHated)二ナトリウム塩=0.04%P/V
メチルパラベン= 0.05%P/V
野生型PLGF−1因子のPLGF−1CG変異タンパク質の血管形成活性と、正の基準としての塩基性線維芽細胞成長因子(bFGF)のPLGF−1CG変異タンパク質の血管形成活性を、Maglione等(「Il Farmaco」上記)によってすでに記述されたヒヨコ絨毛尿膜血管新生試験(CAM)によって比較した。異なる量の変異タンパク質及び野生型因子(0〜3mcg/スポンジ)を1mm3ゼラチンスポンジに吸収させ、続いてCAMの表面に埋め込みした。12日後、試料と接触しているCAM領域を切片にし、着色させ、「点計数」として知られる形態計測技術によって血管形成効果を定量した。具体的には、144個の交点を有するグリッド上でCAM切片を顕微鏡で分析し、その結果を、横断面上で毛細血管が占める交点の割合として表した(血管面積(the area that is vasculised)割合)。図6に示した結果によれば、変異タンパク質と野生型因子の血管形成活性は本質的に同じである。
心臓の虚血及び梗塞に対するPLGF−1CG変異タンパク質の効果を、野生型因子に関してMaglione等(上記)によって記述されたように、動物モデルにおいてイソプレナリンによって誘導された虚血について評価した。毎日160mcg/Kgの単一用量の変異タンパク質、又は同じ体積の賦形剤のみを1〜5日静脈内投与して処置したウサギで実験を行った。1日及び2日目にイソプレナリンを皮下投与した。T波の反転、S波の拡幅、Q波の隆起など主要な虚血性損傷を示す心電図(ECG)の典型的な特性は、試験変異タンパク質で処置した動物よりも、賦形剤のみで処置した動物において明らかに顕著である。処置動物及び未処置動物のECGの変化を、以下の0〜6の点数で評価した。0、病変なし;1、S波の隆起;2、T波の隆起;3、T波下行部の低下;4、S波の拡幅;5、T波の反転;6、Q波の隆起。5日間の試験中のECGポイントによって定義される全曲線下面積も同様に処置動物及び未処置動物に対して計算された。結果を図7に示す。PLGF−1CG変異タンパク質で処置した動物の虚血性損傷がかなり減少した。心電図プロファイルによって明らかなこの結果は、虚血組織の巨視的観察及び微視的観察によって確認された。前記試験は、賦形剤のみで処置した動物の心臓組織において観察されるものと比べ、程度が軽い虚血病変部及び組織変化が存在することを示している。
この試験では、Yamamoto等(上記)によって記述された動物強皮症モデルを使用した。
i)非経口用溶液
非経口用の、純粋なPLGF−1CG25mgとリン酸塩緩衝剤(NaH2PO4/H2O 10mg及びNa2HPO4/2H2O 23mg)33mgを含む凍結乾燥変異タンパク質58ミリグラム、及び食塩水溶液約125mlを、凍結乾燥生成物を希釈剤と使用直前に混合できるように準備されたバイアルに別個に装入する。溶解後に得られた活性物質の濃度は約0.2mg/mlである。
活性物質10mgを含有するある量の凍結乾燥物質を、20%DMSOを含む10%エタノールアルコール水溶液20mlに入れる。次いで、その溶液を、以下の成分を含有する適切なゲル賦形剤とともに添加する。1%Carbopol 940、酢酸ナトリウム15mM(pH4.4)、0.04%p/v二ナトリウムEDTA、0.05%p/vメチルパラベン。最終pH5.5〜6。
Claims (51)
- ヒト又は動物の1型胎盤成長因子(PLGF−1)の単量体の変異タンパク質であって、野生型タンパク質ポリペプチド配列中の少なくとも1個のシステイン残基(Cys)の置換又は脱離を含み、前記置換又は脱離は、生物学的に活性な二量体の形成に影響を及ぼさないが、前記単量体の多量化を防止することを特徴とする変異タンパク質。
- 前記置換又は脱離したCys残基が、前記タンパク質ポリペプチド配列のC末端部分に位置することを特徴とする、請求項1記載の変異タンパク質。
- 変異タンパク質が、配列番号2の125位にあるシステインに対応する、タンパク質前駆体ポリペプチド配列の142位にあるCys残基の置換又は脱離を含むことを特徴とする、請求項2記載の変異タンパク質。
- 142位にある前記Cys残基がグリシン残基(Gly)で置換されたことを特徴とする、請求項3記載の変異タンパク質。
- タンパク質前駆体又は成熟タンパク質の形態をした、請求項1〜4のいずれか一項に記載の変異タンパク質。
- 前記野生型タンパク質のさらに1個又は複数のアミノ酸が、前記変異タンパク質の機能特性を変えずに除去され、置換され、又は付加された、請求項1〜5のいずれか一項に記載の変異タンパク質。
- 二量体の形態をした、請求項1〜6のいずれか一項に記載の変異タンパク質。
- 少なくとも98.5%の前記二量体を含む、請求項7記載の変異タンパク質。
- 請求項1〜6のいずれか一項に記載の変異タンパク質をコードするDNAを含むヌクレオチド配列。
- 前記野生型PLGF−1をコードする配列中のTGC又はTGTコドンが脱離した、又は改変されたことを特徴とする、請求項9記載のヌクレオチド配列。
- TGC又はTGTコドンがGGC、GGT、GGA又はGGGコドンで置換された、請求項10記載のヌクレオチド配列。
- 配列番号1の配列、又は前記DNAの縮退によって生じるその誘導体の382位にあるチミジン塩基がグアニジン塩基で置換された、請求項11記載のヌクレオチド配列。
- 発現の制御及び調節のための非翻訳配列が隣接した、請求項8〜12のいずれか一項に記載のヌクレオチド配列を含む発現系。
- 発現系が、細菌細胞中で誘導され得る発現系であることを特徴とする、請求項13記載の発現系。
- 前記発現が誘導プロモーターの制御下にあることを特徴とする、請求項12又は14に記載の発現系。
- T7ファージRNAポリメラーゼ発現系であり、発現がラクトース、イソプロピル−β−D−チオガラクトピラノシド(IPTG)、又は機能的に等価な類似体によって誘導されることを特徴とする、請求項13〜15のいずれか一項に記載の発現系。
- 請求項12〜16のいずれか一項に記載の発現系によって形質転換された宿主細胞。
- 細胞が細菌細胞であることを特徴とする、請求項17記載の細胞。
- 細菌細胞が大腸菌(E.coli)の菌株に由来することを特徴とする、請求項18記載の細菌細胞。
- 前記変異タンパク質をコードする前記DNAが、前記野生型ヌクレオチド配列を適切に改変したオリゴヌクレオチドをプライマーとして使用したポリメラーゼ連鎖反応(PCR)によって生成されることを特徴とする、請求項8〜12のいずれか一項に記載のヌクレオチド配列の生成方法。
- 配列番号3の配列のオリゴヌクレオチドを5’−3’(順方向)プライマーとして使用し、配列番号4の配列のオリゴヌクレオチドを5’−3’(逆方向)プライマーとして使用する、請求項20記載の方法。
- シグナルタンパク質を含まない前記PLGF−1タンパク質をコードする前記DNA配列を、前記ポリメラーゼ連鎖反応の鋳型として使用する、請求項21記載の方法。
- 前記ポリメラーゼ連鎖反応において得られるDNA配列を完了反応に供し、次いで適切な制限酵素で消化し、適切なベクターにクローン化する、請求項19〜22のいずれか一項に記載の方法。
- 請求項16〜19のいずれか一項に記載の宿主細胞を適切な培地で培養し、前記タンパク質の発現を適切な誘導物質を用いて誘導し、前記細胞を単離して溶解させ、前記変異タンパク質を前記溶解混合物から抽出することを特徴とする、前記PLGF−1因子の変異タンパク質の生成及び抽出方法。
- 前記培地が、1個又は複数の選択剤、酵母抽出物、グリセリン及びアンモニウム塩を含み、動物又はヒト起源の材料を含まない、請求項24記載の方法。
- 前記発現誘導ステップの前に、前記培地の600nmにおける光学濃度(O.D.)が0.2〜50単位に達するまで前記細胞を培養する、請求項24又は25に記載の方法。
- ラクトース、イソプロピル−β−チオガラクトピラノシド(IPTG)、又は機能的に等価な類似体を用いて発現を誘導する、請求項24〜26のいずれか一項に記載の方法。
- 前記細胞溶解を凍結/融解、フレンチプレス、又は他の等価な技術によって実施する、請求項24〜27のいずれか一項に記載の方法。
- 溶解中に放出された封入体を、遠心分離と適切な緩衝剤による洗浄との少なくとも2回のサイクルによって単離する、請求項24〜28のいずれか一項に記載の方法。
- 前記封入体を、尿素、イソチオシアン酸グアニジン、塩酸グアニジン、又は他の変性剤を含有する変性緩衝剤中に溶解させ、場合によってはホモジナイズ又は超音波処理する、請求項24〜29のいずれか一項に記載の方法。
- 前記封入体の溶解後、溶液を希釈し、前記溶液への酸化還元剤の添加と、撹拌下10〜30時間、好ましくは18〜20時間で、温度10℃〜30℃、好ましくは20℃でのインキュベーションとによってタンパク質材料を二量体に再生する、請求項24〜30のいずれか一項に記載の方法。
- 二量体タンパク質精製の少なくとも1つのステップを含む、請求項24〜31のいずれか一項に記載の方法。
- 前記精製ステップがイオン交換クロマトグラフィーからなる、請求項32記載の方法。
- 前記再生ステップから得られる溶液を陰イオン交換カラム上に装入体積/カラム体積比1:1〜10:1、好ましくは10:1で装入する、請求項32又は33に記載の方法。
- 逆相クロマトグラフィーによるカラム精製ステップを含む、請求項32又は33に記載の方法。
- 追加の限外ろ過と、それに続く適切な添加剤の存在下又は非存在下での凍結乾燥を含む、請求項24〜35のいずれか一項に記載の方法。
- 治療処置方法に使用される、請求項7又は8に記載の変異タンパク質。
- 虚血疾患の治療における、請求項37記載の変異タンパク質。
- 心筋組織の虚血、心筋梗塞、虚血性発作及び慢性虚血性心筋疾患、脳虚血及び虚血性発作、腸の虚血、四肢末梢虚血の治療における、請求項38記載の変異タンパク質。
- 強皮症の治療における、請求項37記載の変異タンパク質。
- 皮膚潰よう、傷、火傷の治療、術後治療における、請求項37記載の変異タンパク質。
- 皮膚組織の自然又は早期の老化の治療における、請求項37記載の変異タンパク質。
- 自然又は病的脱毛の治療における、請求項37記載の変異タンパク質。
- 請求項1〜8のいずれか一項に記載の変異タンパク質を認識可能であり、前記野生型PLGF−1と交差反応可能であり、その血管形成活性を中和可能である、ポリクローナル、モノクローナル抗体、又はその機能的に活性な断片。
- PLGF−1の異常産生を伴なう病態の治療において、内因性PLGF−1の血管形成活性を中和する医薬品としての請求項44記載の抗体。
- 各種の腫瘍の治療における請求項44記載の抗体。
- 内因性PLGF−1の異常産生を伴なう病態の診断方法における試薬としての請求項44記載の抗体。
- 請求項7若しくは8に記載の変異タンパク質、又は請求項44記載の抗体、及び薬理学的に許容される賦形剤を含む医薬組成物。
- 非経口、局所、経口、経鼻又は埋め込みに適切な請求項48記載の医薬組成物。
- 請求項7又は8に記載の変異タンパク質及び化粧料として許容される賦形剤を含む化粧組成物。
- 請求項48記載の医薬組成物又は請求項50記載の化粧組成物の調製方法であって、前記PLGF−1変異タンパク質が、薬理学的に又は化粧料として許容される賦形剤、及び他の一般的な添加剤を伴なう方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2002RM000277A ITRM20020277A1 (it) | 2002-05-17 | 2002-05-17 | Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni. |
PCT/IT2003/000296 WO2003097688A2 (en) | 2002-05-17 | 2003-05-19 | Muteins of placental growth factor type 1, preparation method and application thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2006508637A true JP2006508637A (ja) | 2006-03-16 |
JP2006508637A5 JP2006508637A5 (ja) | 2008-10-16 |
JP4230450B2 JP4230450B2 (ja) | 2009-02-25 |
Family
ID=11456311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004506360A Expired - Fee Related JP4230450B2 (ja) | 2002-05-17 | 2003-05-19 | 胎盤成長因子1型の変異タンパク質、その調製方法及び応用 |
Country Status (22)
Country | Link |
---|---|
US (1) | US7314734B2 (ja) |
EP (1) | EP1506295B1 (ja) |
JP (1) | JP4230450B2 (ja) |
KR (1) | KR101022934B1 (ja) |
CN (1) | CN1323167C (ja) |
AT (1) | ATE488590T1 (ja) |
AU (1) | AU2003234066B2 (ja) |
BR (1) | BR0309966A (ja) |
CA (1) | CA2485587C (ja) |
CY (1) | CY1111431T1 (ja) |
DE (1) | DE60334986D1 (ja) |
DK (1) | DK1506295T3 (ja) |
ES (1) | ES2356360T3 (ja) |
HK (1) | HK1079549A1 (ja) |
HR (1) | HRP20041178B1 (ja) |
IT (1) | ITRM20020277A1 (ja) |
MX (1) | MXPA04011405A (ja) |
PL (1) | PL209955B1 (ja) |
PT (1) | PT1506295E (ja) |
RU (1) | RU2344172C2 (ja) |
WO (1) | WO2003097688A2 (ja) |
ZA (1) | ZA200409943B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009100680A (ja) * | 2007-10-23 | 2009-05-14 | Univ Nagoya | ヒト全身性強皮症動物モデルの作製方法、ヒト全身性強皮症動物モデル及びその用途 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004046722A2 (de) | 2002-11-16 | 2004-06-03 | Dade Behring Marburg Gmbh | Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen |
DE102005022047A1 (de) * | 2005-05-09 | 2006-11-30 | Dade Behring Marburg Gmbh | Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung |
CN101918834B (zh) | 2008-01-07 | 2014-05-28 | 奥索临床诊断有限公司 | 用于同时分析能够彼此络合的蛋白质的校准物/对照物 |
CN101918839A (zh) * | 2008-01-07 | 2010-12-15 | 奥索临床诊断有限公司 | sFlt-1:血管生成因子络合物的测定 |
EP2295449A1 (en) * | 2009-09-09 | 2011-03-16 | Dompe PHA.R.MA S.p.A. | PLGF-1 in homodimeric form |
CN103087153B (zh) | 2011-10-28 | 2015-05-06 | 上海市第一人民医院 | 一类新的抑制新生血管的小肽及其应用 |
AU2014273027B2 (en) | 2013-05-31 | 2019-07-04 | Cobiores Nv | Human PlGF-2 for the prevention or treatment of heart failure |
CN109134650A (zh) * | 2018-09-10 | 2019-01-04 | 宁波奥丞生物科技有限公司 | 抗人plgf单克隆抗体的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001085796A2 (en) * | 2000-05-12 | 2001-11-15 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1242149B (it) * | 1990-09-27 | 1994-02-16 | Consiglio Nazionale Ricerche | Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi |
DE69229454T2 (de) * | 1991-03-28 | 2000-01-05 | Merck & Co Inc | Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors |
SE9601245D0 (sv) * | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
DE19748734A1 (de) * | 1997-11-05 | 1999-05-06 | Biotechnolog Forschung Gmbh | Verfahren zur Gewinnung von biologisch aktiven Dimeren von rekombinanten humanen Wachstumsfaktoren aus der Cystein-Knoten-Familie sowie Verwendung der gewonnenen Dimere |
KR20020092779A (ko) * | 1999-06-03 | 2002-12-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 혈관형성 단백질 및 이의 용도 |
-
2002
- 2002-05-17 IT IT2002RM000277A patent/ITRM20020277A1/it unknown
-
2003
- 2003-05-19 KR KR1020047018601A patent/KR101022934B1/ko not_active IP Right Cessation
- 2003-05-19 PL PL372492A patent/PL209955B1/pl unknown
- 2003-05-19 AU AU2003234066A patent/AU2003234066B2/en not_active Ceased
- 2003-05-19 RU RU2004137000/13A patent/RU2344172C2/ru not_active IP Right Cessation
- 2003-05-19 DK DK03727958.5T patent/DK1506295T3/da active
- 2003-05-19 US US10/514,707 patent/US7314734B2/en not_active Expired - Fee Related
- 2003-05-19 CN CNB038112043A patent/CN1323167C/zh not_active Expired - Fee Related
- 2003-05-19 BR BR0309966-0A patent/BR0309966A/pt not_active IP Right Cessation
- 2003-05-19 CA CA2485587A patent/CA2485587C/en not_active Expired - Fee Related
- 2003-05-19 PT PT03727958T patent/PT1506295E/pt unknown
- 2003-05-19 AT AT03727958T patent/ATE488590T1/de active
- 2003-05-19 DE DE60334986T patent/DE60334986D1/de not_active Expired - Lifetime
- 2003-05-19 EP EP03727958A patent/EP1506295B1/en not_active Expired - Lifetime
- 2003-05-19 MX MXPA04011405A patent/MXPA04011405A/es active IP Right Grant
- 2003-05-19 WO PCT/IT2003/000296 patent/WO2003097688A2/en active Application Filing
- 2003-05-19 JP JP2004506360A patent/JP4230450B2/ja not_active Expired - Fee Related
- 2003-05-19 ES ES03727958T patent/ES2356360T3/es not_active Expired - Lifetime
-
2004
- 2004-12-08 ZA ZA2004/09943A patent/ZA200409943B/en unknown
- 2004-12-10 HR HRP20041178AA patent/HRP20041178B1/hr not_active IP Right Cessation
-
2005
- 2005-12-19 HK HK05111674A patent/HK1079549A1/xx not_active IP Right Cessation
-
2011
- 2011-02-16 CY CY20111100200T patent/CY1111431T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001085796A2 (en) * | 2000-05-12 | 2001-11-15 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage |
Non-Patent Citations (2)
Title |
---|
J BIOL CHEM, vol. 276, no. 15, JPN6008012568, 2001, pages 12153 - 12161, ISSN: 0001003435 * |
PROTEIN ENG, vol. 10, no. 4, JPN6008012567, 1997, pages 389 - 398, ISSN: 0001003434 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009100680A (ja) * | 2007-10-23 | 2009-05-14 | Univ Nagoya | ヒト全身性強皮症動物モデルの作製方法、ヒト全身性強皮症動物モデル及びその用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2202075C (en) | Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using | |
JP4230450B2 (ja) | 胎盤成長因子1型の変異タンパク質、その調製方法及び応用 | |
JP4422210B2 (ja) | ケラチノサイト増殖因子アナログ | |
JP2016536306A (ja) | ヒト・リラキシン類似体、その医薬組成物及びその医薬用途 | |
US7807178B2 (en) | Muteins of placental growth factor type I, preparation method and application thereof | |
JP3621431B2 (ja) | 平滑筋細胞増殖因子およびそれをコードする単離されたdna | |
ZA200407707B (en) | Pharmaceutical and cosmetic compositions comprising plgf-1 | |
US8962555B2 (en) | PlGF-1 in homodimeric form | |
AU745815B2 (en) | Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080314 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080616 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080623 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080714 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080722 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080813 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20080813 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080813 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081104 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081203 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111212 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121212 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131212 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |